No Data
CorMedix Price Target Cut to $12.00/Share From $14.00 by Truist Securities
CorMedix Is Maintained at Buy by Truist Securities
Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $12
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $12
Truist Financial analyst Joon Lee maintains $CorMedix(CRMD.US)$ with a buy rating, and adjusts the target price from $14 to $12.According to TipRanks data, the analyst has a success rate of 51.4%
Express News | CorMedix Inc : Truist Securities Cuts Target Price to $12 From $14
Express News | CorMedix Inc. Announces Outpatient Availability of Defencath
No Data